MicroPortNeuroTech™ completes the first commercial implantation of Tubridge™ Flow Diverter in Argentina

Buenos Aires, Argentina, 24 JAN, 2024—MicroPort NeuroTech™ recently completed the first commercial implantation of Tubridge™ Flow Diverter (Tubridge™) in Argentina. The Tubridge™'s exceptional performance garnered high praise from the surgical team.

The surgery was performed by Dr. Carlos Miranda and his team at Sagrado Corazon Hospital. The 68-year-old patient was diagnosed with a fusiform basilar artery aneurysm preoperatively. Given the patient's large vessel size and the wide neck of the fusiform aneurysm, traditional Flow Diverter were inadequate. Nevertheless, the Tubridge™'s comprehensive product specifications successfully addressed this challenge: Dr. Miranda opted for a 6.5mmx45mm Tubridge™ stent and successfully implanted it into the patient's vessel. Leveraging the Tubridge™'s two clearly radiopaque wires, the surgeon could discern, during the procedure, the stent's optimal apposition to the tortuous posterior circulation vessel wall. Post-release, conspicuous retention of contrast agent within the aneurysm underscored the stent's immediate and impactful blood flow redirection.

Tubridge™ offers comprehensive specifications, ranging from 2.5mm to 6.5mm in diameter and up to 45mm in length, addressing the majority of clinical aneurysm cases. In particular, it offers a superior option for large or giant aneurysms. Moreover, braided with nitinol alloy wires, known for their superelasticity and ability to return to a predefined shape, Tubridge™ ensures excellent wall-apposition to tortuous intracranial vessels, facilitating endothelial cell growth and aneurysm healing.

From medical research to clinical application, Tubridge™ has set numerous pioneering records. Moving forward, MicroPortNeuroTech™ remains dedicated to fostering deep collaborations with esteemed clinical experts worldwide, offering premium, comprehensive solutions to cerebrovascular patients worldwide.